Sanofi Consumer Q2 2026 Results: Revenue up 7% YoY

Regulatory filing and what it covers

Sanofi Consumer Healthcare India Limited informed stock exchanges about the availability of its unaudited financial results for the quarter and half-year ended June 30, 2026. The filing also covers an aide-mémoire related to the Q2 2026 results and is positioned as routine regulatory compliance. The company said this disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The stated purpose is transparency around the public release of the company’s financial performance information. Along with the exchange intimation, the company indicated that the results would be made available through standard public channels. The announcement does not indicate any change in accounting policy or a restatement, and it frames the update as a publication and dissemination event.

Newspaper publication: dates and titles disclosed

The company confirmed that the notice for its unaudited financial results was published in newspapers on July 30, 2026. The publications named were Business Standard and Sakal. This is consistent with the disclosure’s focus on public availability of results in addition to exchange filings. Such newspaper publication references typically support compliance with disclosure requirements and improve accessibility for investors who track filings through multiple channels. The filing does not specify the edition or city version of the publications. It also does not provide the full text of the published notice in the provided extract, but it clearly confirms the publication event and date.

Board approval and auditor review for Q2 and H1 2026

Sanofi Consumer Healthcare India said its Board of Directors approved the unaudited financial results for the quarter and half-year ended June 30, 2026 at a meeting held on July 28, 2026. The company submitted the financial results along with a Limited Review Report from its statutory auditors, Price Waterhouse & Co Chartered Accountants LLP. As disclosed, the board meeting commenced at 4:00 p.m. and concluded at 6:00 p.m. The company also stated the results would be published in newspapers and made available on its investor website. The filing positions the limited review as part of SEBI Listing Regulations compliance for unaudited quarterly reporting.

Q2 FY26 financial performance: revenue and profitability

For the quarter ended June 30, 2026, Sanofi Consumer Healthcare India reported revenue from operations of ₹235.7 crore. This was described as a 7% year-on-year increase. Profit before tax (PBT) for Q2 2026 stood at ₹91.9 crore, up 16% year-on-year. Profit for the period was reported at ₹68.8 crore, compared with ₹60.7 crore in the corresponding quarter of the previous year. The company also disclosed an earnings per share (EPS) of ₹29.87 for the quarter in one of the results summaries provided. Separately, the company attributed performance support to the relaunch of key brands including Combiflam, Allegra, and Depura.

Half-year numbers: revenue and profit for the period

For the half-year ended June 30, 2026, the company reported revenue of ₹464.9 crore. The same half-year period profit for the period was disclosed at ₹136.6 crore. In an earnings summary note included in the provided material, revenue from operations for the half year was also presented as ₹4,649 million, which converts to ₹464.9 crore. That note also stated half-year revenue was up 18% year-on-year. It added that profit before tax for the half year increased by 25% year-on-year, though the absolute half-year PBT number was not included in the excerpt. The half-year commentary also split growth between domestic and export channels, with different year-on-year patterns.

Sales mix commentary: domestic and exports

The earnings summary stated that in Q2 2026, domestic sales grew 12% year-on-year while export sales declined 9% on a high base. For the half year ended June 30, 2026, the note said domestic sales increased 14% year-on-year and export sales rose 27% on a low base. These channel details matter because they provide context beyond the consolidated revenue figure and indicate whether growth is broad-based or concentrated. The filing does not provide absolute domestic versus export revenue in the excerpt, only growth rates. It also does not specify product-level contribution beyond the brand relaunch reference.

Cash position disclosed in the Q2 summary

The Q2 2026 earnings summary included a cash and cash equivalents figure of ₹490.2 crore as of June 30, 2026. It also provided the comparative figure of ₹374.8 crore as of December 31, 2025. These numbers were originally presented in million (₹4,902 million and ₹3,748 million) and are converted here into crore for consistency. The disclosure does not break down the drivers of the cash movement in the provided text. It also does not provide debt figures in the excerpt, so net cash cannot be inferred. Still, the cash disclosure adds a balance-sheet datapoint alongside the profit and revenue numbers.

Other disclosed references: earlier quarter approval and webcast

The material also references an earlier board meeting held on April 28, 2026, which considered and approved unaudited financial results for the quarter ended March 31, 2026. That disclosure cites compliance with Regulation 33 and notes that statutory auditors issued a limited review report with an unmodified conclusion for that quarter. Separately, there is a reference stating the statutory auditors issued an unqualified audit report on the annual accounts for the year ended December 31, 2025. The combined material also notes that second quarter 2026 results would be reviewed by management during a live audio webcast with the financial community on July 30, 2026. These items collectively describe the company’s reporting cadence and investor communication approach as captured in the shared text.

Key numbers table (₹ crore)

Why this update matters for investors

This filing is primarily about dissemination and compliance: it documents when and where the Q2 and half-year unaudited results were made public, and confirms board approval and auditor limited review. For investors, the operational headline is the 7% year-on-year increase in Q2 revenue to ₹235.7 crore alongside stronger profitability, with Q2 PBT rising 16% year-on-year. The half-year revenue figure of ₹464.9 crore and profit for the period of ₹136.6 crore provide a broader view beyond the quarter. The disclosure also adds useful context through domestic and export growth rates and the cash balance update. The next step referenced in the material is the management review of the results via a webcast scheduled for July 30, 2026.